Rationale: Hereditary hemochromatosis can be divided into HFE-and non-HFE-related based on genetic mutations in different genes. HFE-related hemochromatosis is the most common inherited genetic disease in European populations but rare in Asia-pacific region. Recently, non-HFE-related hemochromatosis has been reported in patients from the Asian countries.
Introduction
Hereditary hemochromatosis (HH) is a genetic disorder characterized by iron deposition and tissue injury in multiple organs. [1] The genetic bases for hemochromatosis can be divided principally into hemochromatosis (HFE) gene mutations and non-HFE mutations. [2] The principal HFE gene defect was first identified in 1996, and is a G-to-A missense mutation, leading to the substitution of tyrosine for cysteine at amino acid position 282 of the protein product (C282Y); the other 2 relatively common HFE mutations were H63D and S65C. [3] HFE-related HH is the most common inherited genetic disease in European populations. [1] Mutations in all the currently known genes implicated in non-HFE HH, such as hemojuvelin (HJV), hepcidin antimicrobial peptide (HAMP), transferrin receptor 2 (TFR2), and solute carrier family 40 member 1 (SLC40A1), have been reported in patients from the Asia-Pacific region. [2] Further, a meta-analysis found that 80.6% (2260/2802) of HH patients are homozygous for the C282Y mutation of HFE, [3] yet this mutation is not found in Chinese patients. [4] Here, we report a novel SLC40A1 mutation, IVS 3+10 del gtt, in a Chinese Han woman with severe iron overload disease.
Clinical report

Patient identification
A 48-year-old female patient who had been suffering from asthenia and intermittent vomiting for 9 months was admitted to our hospital. She had no other gastrointestinal symptoms, but had been diagnosed with diabetes mellitus for 2 years. She had never taken supplemental iron and did not consume alcohol. . Iron studies showed: iron 34.34 mmol/L, transferrin saturation 100%, and ferritin 7078 mg/L. Magnetic resonance imaging (MRI) of the abdomen showed a significant iron overload in the liver and spleen (Fig. 1) . A liver biopsy was performed for diagnostic purposes and staging of her liver disease. The specimen obtained was prepared with hematoxylin/ eosin and Berlin blue staining. Histological examination of the specimen showed grade 3 iron stores (using the Scheuer scoring system), predominantly in parenchymal cells, but with significant iron deposits in Kupffer cells and portal tract macrophages (Fig.  2 ). In addition, periportal fibrosis was observed, but no cirrhosis was evident.
Detection of genetic mutations
Informed consent was obtained before taking a blood sample for gene analysis of HFE (C282Y and H63D), HJV, HAMP, TFR2, and SLC40A1. Efforts were made to contact and obtain blood samples from family members. However, owing to circumstances beyond our control, none could be contacted. Genomic DNA was extracted from peripheral blood leukocytes using the Genomic DNA Purification Kit (Qiagen, Valencia, CA). Whole exons were amplified from the HFE, HJV, HAMP, TFR2, and SLC40A1 genes, and their associated boundary regions by polymerase chain reaction (PCR) using the primers described in our previous study. [5] Amplification was performed with an initial denaturation of 1 cycle of 95°C for 5 minutes, followed by 38 cycles of 95°C for 1 minute, annealing at 50 to 60°C for 70 seconds, and 72°C for 5 minutes. PCR products were sequenced using the ABI3730 automated DNA sequencer. The cDNA reference sequence was submitted to GenBank (https:// www.ncbi.nlm.nih.gov/genbank/) and analyzed by ExPASy (http://web.expasy.org/translate/). The results showed that the patient had a splicing mutation, IVS3+10 del gtt, in the SLC40A1 gene (Fig. 3) . No mutations were identified in the other 4 genes.
Reverse transcriptase-PCR (RT-PCR) analysis of SLC40A1 gene transcripts
Total RNA was isolated from formalin-fixed paraffin-embedded tissue of the patient using the RNeasy FFPE Kit (Qiagen, Valencia, CA) according to the manufactory's protocol, and the reverse-transcript was conducted using the High-Capacity cDNA Reverse Transcription Kits (Applied Bosystems, Foster city, CA). cDNA of BEL7402 cell line and normal liver tissue were provided by Dr Anjian Xu (Experimental Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China) and used as control for RT-PCR analysis. RT-PCR covering the coding sequence of exons 3 to 4 of SLC40A1 was performed with the primers as follows: 5 0 -TTGCGGTGTCTGTGTTTCTG-3 0 (in exon 3) and 5 0 -AGGTCTGGGCCACTTTAAGT-3 0 (in exon 4) for SLC40A1, and 5 0 -GAGTCAACGGATTTGGTCGT-3 0 and 5 0 -GAGTCAACGGATTTGGTCGT-3 0 for GAPDH as control. The reactions were performed in an ABI GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA) with the following program: denaturation for 30 seconds at 94°C, annealing for 30 seconds at 60°C, and elongation for 30 seconds at 72°C for 35 cycles; the final extension at 72°C for 7 minutes. Equal volumes of each PCR sample were subjected to electrophoresis in a 1.5% agarose gel, and the PCR product of SLC40A1 was conducted sequencing with the same primer for PCR.
The results showed a substantial reduction in the basal levels of SLC40A1 mRNA in the case with SLC40A1 IVS3+10 del gtt mutation compared with that of the controls (Fig. 4A) , suggesting 
the SLC40A1 IVS3+10 del gtt mutation may lead to abnormal splicing of mRNA.
Immunohistochemical analysis of ferroportin
Sections (4 mm thick) were cut for immunohistochemistry (IHC) analysis. After deparaffinization of the slides, endogenous peroxidase activity was blocked with 0.3% H 2 O 2 , in methanol for 30 minutes. Antigen retrieval was carried out in antigen unmasking solution (H-3300, Vector) with microwaving for 15 minutes, keeping the solution boiling and then treating with 5% skimmed milk in phosphate buffer saline-0.1% albumin from bovine serum for at least 1 hour at room temperature to block nonspecific staining. Immunohistochemical staining was performed using antibodies against ferroportin (NBP1-21502, Novus) at a dilution of 1:800 at 4°C overnight. Secondary antibody (MP-7401, Vector) was used at 37°C for 1 hour, and visualization of antigen-antibody reactions were achieved with 3,3'-diaminobenzidine (DAB, Vector kit SK-4100). Increased staining of ferroportin was shown in the cell membranes in the liver tissue with the SLC40A1 IVS3+10 del gtt compared with that of the normal liver tissue, suggesting the increased membrane localization of ferroportin (Fig. 4B ).
Discussion
Currently, 4 major categories of hereditary hemochromatosis have been established, including HFE-related or type 1 hemochromatosis (which is common in Caucasians), type 2 (A and B) hemochromatosis with mutation in HJV or HAMP, type 3 hemochromatosis with mutation in TFR2, and type 4 hemochromatosis (ferroportin disease) with mutation in SLC40A1. [6] In this report, we describe the clinical and laboratory features of a case diagnosed with HH, who has a previously unrecognized ferroportin mutation, specifically, SLC40A1: IVS3+10 del gtt, which is a classical splicing mutation. To our knowledge, more than 30 case reports of ferroportin disease had been reported, [7] but all the mutations reported in those reports were missense mutation without functional analysis, so the biological consequence of the identified mutations remains to be explored. However, the case in the present study is the first report to identify a classical splicing mutation in the SLC40A1 gene in type 4B hemochromatosis.
Ferroportin disease (type 4 HH) is due to pathogenic mutations in the SLC40A1 gene, which encodes a main iron export protein called "ferroportin1/IREG1/MTP1." [8] By altering the physicochemical properties of this protein, these mutations cause iron overload via an intracellular retention mechanism. [9] According to the different phenotypes, ferroportin disease is divided into 2 types: type 4A (classical ferroportin disease) and type 4B (nonclassical ferroportin disease). [9] The phenotypic features of type 4A and type 4B HH are summarized in Table 1 . [7] [8] [9] It is assumed that the phenotypes of patients with SLC40A1 mutations vary depending on the mutation. [10] Mutations leading to ferroportin that is either not present normally at the cell surface or has defective iron export activity (loss of function) are associated with iron deposition in Kupffer cells and low transferrin saturation, [10] and define type 4A. Those mutated ferroportin that cannot be internalized after hepcidin binding (gain of function) are associated with iron deposition in hepatocytes and elevated transferrin saturation, [10] and define type 4B. A systemic meta-analysis of 176 individuals reported that SLC40A1 mutations, namely, V162del, D157N, D181V, G80V, Q182H, and R489K, may impair ferroportin's iron export function, and are common mutations for type 4A HH. Conversely, the mutations Y64N, V72F, and Y501C confer hepcidin resistance and are common mutations for type 4B HH. [7] Chen et al. [11] reported the first type 4B HH case in the Chinese Han population. They found a novel heterozygous mutation (p. Cys326Phe) in the SLC40A1 gene, which results in hepcidin resistance, although this finding needs in vitro confirmation. Our case here is the first case report of type 4B HH associated with the identified IVS3+10 del gtt mutation in the SLC40A1 gene. The typical splicing mutation, IVS3+10 del gtt, is located in intron 3 of the SLC40A1 gene, 9 bases away from the end base of exon 3. Subsequently, this mutation may lead to a splicing error that results in incorrect assembly of ferroportin protein and a consequent change in function. In a recent study, a single heterozygous MSX1 IVS1+5G/A mutation was identified in a case affected with tooth agenesis. Although RNA sequencing showed correct joining of exon 1 and exon 2 sequences, a substantial reduction of the levels of MSX1 mRNA was observed, indicating that the novel variant may reduce efficiency of the splicing of pre-mRNA, and thus lead to the decrease of mRNA level. [12] Previous studies have demonstrated the reduced efficiency of pre-mRNA splicing in other genes containing the intronic mutation downstream of the consensus donor site. [13] In the above study, primer sets targeting exon 1 and 2 sequences were used to assess cDNA replicates. Compared with unaffected individuals, significantly reduced MSX1 mRNA expression was observed in the proband. Similarly, in the present study, primer sets targeting exon 3 and 4 sequences were used to assess cDNA replicates, and the results showed significantly reduced SLC40A1 mRNA expression compared with that of the controls, suggesting the SLC40A1 IVS3+10 del gtt may lead to abnormal splicing of mRNA.
In addition, the IHC analysis of ferroportin showed increased staining of ferroportin in the cell membranes in the liver tissue with the SLC40A1 IVS3+10 del gtt, compared with that of the normal liver tissue. The increased membrane localization of ferroportin, one of the characteristics of type 4B HH, may result from the abnormal SLC40A1 transcripts, of which the encoded mutated ferroportin cannot be internalized after hepcidin binding.
This patient presented with abnormal liver function, diabetes mellitus, hyperferritinemia, and high transferrin saturation, with compound iron overload in parenchymal cells and Kupffer cells, periportal fibrosis on liver biopsy, and was heterozygous for a novel mutation in the SLC40A1 gene. Therefore, the final diagnosis of the patient was type 4B (nonclassical) hereditary hemochromatosis.
Conclusions
In conclusion, we have identified the IVS3+10 del gtt mutation of ferroportin 1 in a Chinese individual. This mutation is associated with high transferrin saturation, parenchymal iron loading, and advanced fibrosis. This case is the first report to identify a classical splicing mutation in the SLC40A1 gene and emphasizes the importance of non-HFE mutations in hereditary hemochromatosis in Asian countries.
